The Clear Roads research program unites transportation experts nationwide to advance winter maintenance strategies.

The EMA's CHMP has recommended not renewing the marketing authorization for Translarna (ataluren) for Duchenne muscular dystrophy patients with nonsense mutations.

Rural bladder cancer patients showed better quality of life outcomes after radical cystectomy compared to urban residents, with social support playing a key role in their recovery.

A study by the University of Nottingham found a nearly 50% increased dementia risk in patients aged 55+ using strong anticholinergics daily for three years or more.

The RAPID_REVIVE study, led by Frankfurt University Hospital, is a phase 2 trial investigating treatments for post-COVID syndrome (PCS).

JelloX Biotech's 3D pathology technology identified significantly more HER2-low and HER2-ultralow breast tumors compared to conventional diagnostic methods in a study with National Taiwan University Hospital.

Researchers at Johns Hopkins University have developed a novel blood test to detect postpartum depression (PPD) by analyzing extracellular vesicles (EVs) containing brain-derived RNA.

Cure Parkinson's has announced £1 million in funding for SLEIPNIR, a new multi-arm clinical trial platform in Norway that will test up to three potentially disease-modifying Parkinson's treatments simultaneously against one placebo group.

The University of Virginia is launching a clinical trial to evaluate an AI-powered "Bolus Priming System with Reinforcement Learning" (BPS_RL) for automated insulin delivery in Type 1 diabetes patients.

Purple Biotech initiates Phase 2 trial of NT219, a novel dual-pathway inhibitor, in combination with pembrolizumab or cetuximab for treating recurrent/metastatic head and neck cancer.

A study conducted by Johns Hopkins University School of Medicine found that a high dose of psilocybin, administered under supportive conditions, significantly decreased symptoms of depression and anxiety in cancer patients. These effects were sustained for up to six months, with participants reporting improved quality of life and decreased death anxiety.

A large, multi-center trial (ROCKet) is underway to assess if intravenous ketamine, administered perioperatively, can reduce chronic post-surgical pain (CPSP) at 3 months post-surgery.

Medera Inc. has completed Cohort A (low-dose) and initiated dosing in Cohort B (high-dose) of the MUSIC-HFpEF trial, evaluating SRD-002 for heart failure with preserved ejection fraction (HFpEF).

Lytix Biopharma has dosed the first patient in a Phase II trial (NeoLIPA) evaluating LTX-315 in early-stage melanoma patients, addressing a significant unmet need.

TRiCares has successfully implanted its Topaz transcatheter tricuspid heart valve replacement (TTVR) system in the first patients in a U.S. Early Feasibility Study.

A recent study identifies maternal and fetal vascular malperfusion as significant factors in retinopathy of prematurity (ROP) risk, enhancing current screening methods.

A new study evaluates the effectiveness of One Step Nucleic Acid Amplification (OSNA) in detecting lymph node metastases in endometrial cancer, comparing it to the traditional ultrastaging method. The study aims to provide a faster, standardized analysis of lymph nodes, potentially expediting patient treatment and management.

Immunotherapy, particularly checkpoint inhibitors, has become a significant treatment option for bladder cancer, with established roles in second-line therapy for metastatic urothelial cancers and as maintenance therapy post-platinum-based chemotherapy. It is also suitable for first-line treatment in PD-L1 high or platinum-ineligible patients and offers an alternative for high-risk BCG-refractory patients.

The NIH has initiated a Phase 1 clinical trial of LASSARAB, a novel vaccine candidate for Lassa fever, a viral hemorrhagic disease that can be fatal and causes permanent hearing loss in up to one-third of patients.

• Aurion Biotech has commercially launched Vyznova (neltependocel) in Japan, the first approved allogeneic cell therapy for corneal endothelial disease. • Vyznova offers a new treatment option for bullous keratopathy, addressing the critical shortage of donor corneas for traditional transplants. • Clinical trials in the U.S. and Canada are underway, with the FDA granting Breakthrough Therapy and Regenerative Medicine Advanced Therapy designations to Aurion Biotech. • Vyznova's development stems from over 25 years of research pioneered by Professor Shigeru Kinoshita at Kyoto Prefecture University of Medicine.